Leda Mannent
Sanofi (France)(FR)Sanofi (Mexico)(MX)
Publications by Year
Research Areas
Asthma and respiratory diseases, Sinusitis and nasal conditions, Allergic Rhinitis and Sensitization, Eosinophilic Esophagitis, Dermatology and Skin Diseases
Most-Cited Works
- → Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials(2019)1,406 cited
- → Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis(2016)775 cited
- → Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis(2019)437 cited
- → Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis(2022)422 cited
- → Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts(2023)421 cited
- → Conjunctivitis in dupilumab clinical trials(2019)411 cited
- → Chronic Rhinosinusitis with Nasal Polyps and Asthma(2020)378 cited
- → Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial(2022)244 cited
- → Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis(2022)216 cited
- → Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials(2023)204 cited